Responder Definition in Clinical Stem Cell Trials in Cardiology: Will the Real Responder Please Stand Up?

Circulation Research

Volumn 119, Issue 4, 2016, Pages 514-518

  Zwetsloot, Peter Paul ^a   Gremmels, Hendrik ^a   Assmus, Birgit ^b   Koudstaal, Stefan ^a   Sluijter, Joost P G ^a,c   Zeiher, Andreas M ^a   Chamuleau, Steven A J ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GOETHE UNIVERSITY   (Germany)

^c INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

Author keywords

bone marrow; cell transplantation; clinical trial; myocardial infarction

Indexed keywords

ADULT; BONE MARROW DERIVED MONONUCLEAR CELL; CARDIOLOGY; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SHORT SURVEY; SMOKING; STEM CELL TRANSPLANTATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); MULTICENTER STUDY (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

CARDIOLOGY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84982984220     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308733     Document Type: Short Survey

References (22)

1. Delewi R, Hirsch A, Tijssen JG, et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of STsegment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J. 2014;35:989-998. doi: 10.1093/eurheartj/eht372.
2. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res. 2008;102:1319-1330. doi: 10.1161/ CIRCRESAHA.108.175943.
3. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-1221. doi: 10.1056/NEJMoa060186.
4. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 2000;19:1059-1079.
5. R development core team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2015. http://www.R-project.org.
6. Gyongyosi M, Wojakowski W, Navarese EP, Moye LA; ACCRUE Investigators. Meta-analyses of human cell-based cardiac regeneration therapies: controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ Res. 2016;118:1254-1263. doi: 10.1161/ CIRCRESAHA.115.307347.
7. Gyongyosi M, Wojakowski W, Lemarchand P, et al; ACCRUE Investigators. Meta-analysis of cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116:1346-1360. doi: 10.1161/CIRCRESAHA.116.304346.
8. Ana Lucia C, Elaine F, Marcos FM, Paula SA, Katashi O, Beatriz BM, Silmeia GZ, Sergio ARP, Leonardo AMZ. Waist circumference, but not body mass index, is a predictor of ventricular remodeling after anterior myocardial infarction. Nutrition. 2013;29:122-126. doi: 10.1016/j.nut.2012.04.020.
9. Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, Vatten LJ. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation. 2016;133:639-649. doi: 10.1161/ CIRCULATIONAHA.115.016801.
10. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA; CARE Study. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003;42:1446-1453.
11. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, Inden Y, Murohara T. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol. 2004;24:1442-1447. doi: 10.1161/01.ATV.0000135655.52088. c5.
12. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo A, Agostini C, Avogaro A. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45:1449-1457. doi: 10.1016/j.jacc.2004.11.067.
13. Muller-Ehmsen J, Braun D, Schneider T, Pfister R, Worm N, Wielckens K, Scheid C, Frommolt P, Flesch M. Decreased number of circulating progenitor cells in obesity: beneficial effects of weight reduction. Eur Heart J. 2008;29:1560-1568. doi: 10.1093/eurheartj/ehn213.
14. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007. doi: 10.1056/ NEJMoa043814.
15. Wojakowski W, Tendera M, Michałowska A, Majka M, Kucia M, Maślankiewicz K, Wyderka R, Ochała A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation. 2004;110:3213-3220. doi: 10.1161/01.CIR.0000147609.39780.02.
16. Ling L, Shen Y, Wang K, Jiang C, Fang C, Ferro A, Kang L, Xu B. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization. PLoS One. 2012;7:e50739. doi: 10.1371/journal. pone.0050739.
17. Italo P, Ilaria D, Luca Di V, Giovanni LDM, Alessandra T, Antonio ML, Alessandra P, Maurizio CC, Luigi MB, Filippo C. Differential levels of circulating progenitor cells in acute coronary syndrome patients with a first event versus patients with recurring events. Int J Cardiol. 2011;149:50-54. doi: 10.1016/j.ijcard.2009.11.039.
18. Taylor DA, Perin EC, Willerson JT, et al. Identification of bone marrow cell subpopulations associated with improved functional outcomes in patients with chronic left ventricular dysfunction: An embedded cohort evaluation of the FOCUS-CCTRN trial [published online ahead of print November 19 [2015]. Cell Transplant.
19. Schutt RC, Trachtenberg BH, Cooke JP, et al; Cardiovascular Cell Therapy Research Network (CCTRN). Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. Circ Res. 2015;116:99-107. doi: 10.1161/CIRCRESAHA.116.304710.
20. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH, Martin H, Zeiher AM, Dimmeler S. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004;109:1615-1622. doi: 10.1161/01.CIR.0000124476.32871.E3.
21. Li TS, Kubo M, Ueda K, Murakami M, Ohshima M, Kobayashi T, Tanaka T, Shirasawa B, Mikamo A, Hamano K. Identification of risk factors related to poor angiogenic potency of bone marrow cells from different patients. Circulation. 2009;120:S255-S261. doi: 10.1161/ CIRCULATIONAHA.108.837039.
22. Leon AC, Heo M. Sample sizes required to detect interactions between two binary fixed-effects in a mixed-effects linear regression model. Comput Stat Data Anal. 2009;53:603-608. doi: 10.1016/j. csda.2008.06.010.